Rigel Pharmaceuticals Inc (RIGL) — Capital Reinvestment Ratio

Latest as of December 2025: 0.00x

Rigel Pharmaceuticals Inc (RIGL) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($21.98 Million) in capital expenditures ($12.00K). See debt-free asset ratio of Rigel Pharmaceuticals Inc to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$21.98 Million
USD

Capital Expenditures

$12.00K
USD

Data as of

Dec 2025
Most recent filing

Rigel Pharmaceuticals Inc Capital Reinvestment Ratio (2010–2024)

This chart tracks Rigel Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods. Check RIGL cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Rigel Pharmaceuticals Inc (2010–2024)

Year-by-year Capital Reinvestment Ratio for Rigel Pharmaceuticals Inc from 2010 to 2024. For live market cap and broader valuation context, see RIGL stock market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.01x $31.47 Million $396.00K ▼ -88.2%
2021 0.11x $5.88 Million $627.00K ▲ +40.1%
2010 0.08x $46.74 Million $3.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow